

# Marco Boscaro

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8424125/publications.pdf>

Version: 2024-02-01

295  
papers

16,771  
citations

17405

63  
h-index

20307

116  
g-index

307  
all docs

307  
docs citations

307  
times ranked

10976  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Prospective Study of the Prevalence of Primary Aldosteronism in 1,125 Hypertensive Patients. <i>Journal of the American College of Cardiology</i> , 2006, 48, 2293-2300.	1.2	1,236
2	Diagnosis and Complications of Cushing's Syndrome: A Consensus Statement. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 5593-5602.	1.8	1,184
3	Treatment of Adrenocorticotropin-Dependent Cushing's Syndrome: A Consensus Statement. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 2454-2462.	1.8	774
4	Prevalence and natural history of adrenal incidentalomas. <i>European Journal of Endocrinology</i> , 2003, 149, 273-285.	1.9	500
5	Cushing's syndrome. <i>Lancet</i> , 2001, 357, 783-791.	6.3	332
6	Treatment of Pituitary-Dependent Cushing's Disease with the Multireceptor Ligand Somatostatin Analog Pasireotide (SOM230): A Multicenter, Phase II Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 115-122.	1.8	274
7	High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. <i>Clinical Endocrinology</i> , 2004, 61, 768-777.	1.2	239
8	Risk factors and long-term outcome in pituitary-dependent Cushing's disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 2647-2652.	1.8	226
9	Approach to the Patient with Possible Cushing's Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 3121-3131.	1.8	219
10	Risk Factors and Long-Term Follow-Up of Adrenal Incidentalomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 520-526.	1.8	203
11	Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. <i>Fertility and Sterility</i> , 2005, 84, 662-671.	0.5	195
12	Ketoconazole treatment in Cushing's syndrome: experience in 34 patients. <i>Clinical Endocrinology</i> , 1991, 35, 347-352.	1.2	194
13	Expanding role of AMPK in endocrinology. <i>Trends in Endocrinology and Metabolism</i> , 2006, 17, 205-215.	3.1	190
14	Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. <i>Fertility and Sterility</i> , 2009, 91, 1785-1792.	0.5	170
15	Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. <i>Journal of Hypertension</i> , 2007, 25, 177-186.	0.3	167
16	Quality of life of hirsute women. <i>Postgraduate Medical Journal</i> , 1993, 69, 186-189.	0.9	162
17	The diagnostic performance of urinary free cortisol is better than the cortisol:cortisone ratio in detecting de novo Cushing's syndrome: the use of a LC-MS/MS method in routine clinical practice. <i>European Journal of Endocrinology</i> , 2014, 171, 1-7.	1.9	161
18	Incidentally Discovered Adrenal Tumors: Endocrine and Scintigraphic Correlates. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 55-62.	1.8	160

#	ARTICLE	IF	CITATIONS
19	LCI699, a Potent 11 $\beta$ -hydroxylase Inhibitor, Normalizes Urinary Cortisol in Patients With Cushing's Disease: Results From a Multicenter, Proof-of-Concept Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 1375-1383.	1.8	160
20	Left ventricular structural and functional characteristics in Cushing's syndrome. <i>Journal of the American College of Cardiology</i> , 2003, 41, 2275-2279.	1.2	159
21	Adrenalectomy Lowers Incident Atrial Fibrillation in Primary Aldosteronism Patients at Long Term. <i>Hypertension</i> , 2018, 71, 585-591.	1.3	149
22	AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome. <i>FASEB Journal</i> , 2008, 22, 1672-1683.	0.2	148
23	Pathophysiology of Dyslipidemia in Cushing's Syndrome. <i>Neuroendocrinology</i> , 2010, 92, 86-90.	1.2	147
24	Anticoagulant Prophylaxis Markedly Reduces Thromboembolic Complications in Cushing's Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 3662-3666.	1.8	141
25	Development of overt Cushing's syndrome in patients with adrenal incidentaloma. <i>European Journal of Endocrinology</i> , 2002, 146, 61-66.	1.9	140
26	Clinical Correlates of Major Depression in Cushing's Disease. <i>Psychopathology</i> , 1998, 31, 302-306.	1.1	134
27	Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. <i>Journal of Hypertension</i> , 2006, 24, 737-745.	0.3	133
28	Aldosterone as a cardiovascular risk factor. <i>Trends in Endocrinology and Metabolism</i> , 2005, 16, 104-107.	3.1	128
29	Diagnosis of primary aldosteronism: from screening to subtype differentiation. <i>Trends in Endocrinology and Metabolism</i> , 2005, 16, 114-119.	3.1	125
30	Diagnosis of Glucocorticoid-Remediable Aldosteronism in Primary Aldosteronism: Aldosterone Response to Dexamethasone and Long Polymerase Chain Reaction for Chimeric Gene. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 2573-2575.	1.8	121
31	Anticoagulant Prophylaxis Markedly Reduces Thromboembolic Complications in Cushing's Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 3662-3666.	1.8	118
32	Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 17-26.	5.5	116
33	Coenzyme q10 supplementation in infertile men with idiopathic asthenozoospermia: an open, uncontrolled pilot study. <i>Fertility and Sterility</i> , 2004, 81, 93-98.	0.5	115
34	Prolonged Treatment of Cushing's Disease by Ketoconazole. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1985, 61, 718-722.	1.8	114
35	Role of Nitric Oxide Concentrations on Human Sperm Motility. <i>Journal of Andrology</i> , 2004, 25, 245-249.	2.0	114
36	THERAPY OF ENDOCRINE DISEASE: Outcomes in patients with Cushing's disease undergoing transphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. <i>European Journal of Endocrinology</i> , 2015, 172, R227-R239.	1.9	114

#	ARTICLE	IF	CITATIONS
37	Conventional and Nuclear Medicine Imaging in Ectopic Cushing's Syndrome: A Systematic Review. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3231-3244.	1.8	113
38	Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. <i>European Journal of Endocrinology</i> , 2010, 163, 301-308.	1.9	111
39	I. Adrenal Cortex and Steroid 21-Hydroxylase Autoantibodies in Adult Patients with Organ-Specific Autoimmune Diseases: Markers of Low Progression to Clinical Addison's Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 932-938.	1.8	109
40	Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing's syndrome. <i>Blood Coagulation and Fibrinolysis</i> , 1999, 10, 145-152.	0.5	96
41	Effect of glucocorticoids on adiponectin: a study in healthy subjects and in Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2004, 150, 339-344.	1.9	95
42	Adrenal incidentaloma. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2012, 26, 405-419.	2.2	94
43	Cardiovascular Risk In Cushing's Syndrome. <i>Pituitary</i> , 2004, 7, 253-256.	1.6	93
44	DIAGNOSIS AND MANAGEMENT OF ADRENAL INCIDENTALOMAS. <i>Journal of Urology</i> , 2000, 163, 398-407.	0.2	91
45	The fibrinolytic potential in patients with Cushing's disease. <i>Blood Coagulation and Fibrinolysis</i> , 1992, 3, 789-794.	0.5	89
46	Glucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management. <i>Endocrine Reviews</i> , 2017, 38, 189-219.	8.9	88
47	Effect of Adrenocorticotrophic Hormone Stimulation During Adrenal Vein Sampling in Primary Aldosteronism. <i>Hypertension</i> , 2012, 59, 840-846.	1.3	87
48	MEDICAL THERAPY FOR CUSHING'S DISEASE. <i>Endocrinology and Metabolism Clinics of North America</i> , 1999, 28, 211-222.	1.2	83
49	Glucocorticoid-dependent hypertension. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1992, 43, 409-413.	1.2	82
50	Course of Depression in Cushing's Syndrome: Response to Treatment and Comparison with Graves' Disease. <i>Hormone Research</i> , 1993, 39, 202-206.	1.8	82
51	Persistent Psychological Distress in Patients Treated for Endocrine Disease. <i>Psychotherapy and Psychosomatics</i> , 2004, 73, 78-83.	4.0	82
52	Adrenocortical Carcinoma: Experience in 45 Patients. <i>Oncology</i> , 1997, 54, 490-496.	0.9	76
53	The Diagnosis of Cushing's Syndrome. <i>Archives of Internal Medicine</i> , 2000, 160, 3045.	4.3	76
54	Changes in Adenosine 5'-Monophosphate-Activated Protein Kinase as a Mechanism of Visceral Obesity in Cushing's Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 4969-4973.	1.8	76

#	ARTICLE	IF	CITATIONS
55	Distinctive modulation of inflammatory and metabolic parameters in relation to zinc nutritional status in adult overweight/obese subjects. <i>Journal of Nutritional Biochemistry</i> , 2010, 21, 432-437.	1.9	73
56	Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4110.	1.8	73
57	<i>IN VIVO</i> AND <i>IN VITRO</i> STUDIES ON THE EFFECT OF METOCLOPRAMIDE ON ALDOSTERONE SECRETION. <i>Clinical Endocrinology</i> , 1980, 13, 45-50.	1.2	71
58	Increased Factor VIII Associated Activities in Cushing's Syndrome: A Probable Hypercoagulable State. <i>Thrombosis and Haemostasis</i> , 1982, 47, 116-117.	1.8	71
59	Use of the Desmopressin Test in the Differential Diagnosis of Pseudo-Cushing State from Cushing's Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 1115-1122.	1.8	70
60	Advances in the epidemiology, pathogenesis, and management of Cushing's syndrome complications. <i>Journal of Endocrinological Investigation</i> , 2012, 35, 434-448.	1.8	69
61	Further Studies on the Hypercoagulable State of Patients with Cushing's Syndrome. <i>Thrombosis and Haemostasis</i> , 1985, 54, 518-520.	1.8	68
62	Adipose tissue 11 $\beta$ -hydroxysteroid dehydrogenase type 1 expression in obesity and Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2006, 155, 435-441.	1.9	67
63	Sexual Symptoms in Endocrine Diseases: Psychosomatic Perspectives. <i>Psychotherapy and Psychosomatics</i> , 2007, 76, 134-140.	4.0	67
64	Bone health and aldosterone excess. <i>Osteoporosis International</i> , 2013, 24, 2801-2807.	1.3	65
65	Cyclical Cushing's Syndrome in a Patient with a Bronchial Neuroendocrine Tumor (Typical Carcinoid) Expressing Ghrelin and Growth Hormone Secretagogue Receptors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 5834-5840.	1.8	64
66	Quantitative Value of Aldosterone-Renin Ratio for Detection of Aldosterone-Producing Adenoma: The Aldosterone-Renin Ratio for Primary Aldosteronism (AQUARR) Study. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	64
67	An analysis of different therapeutic options in patients with Cushing's syndrome due to bilateral macronodular adrenal hyperplasia: a single-centre experience. <i>Clinical Endocrinology</i> , 2015, 82, 808-815.	1.2	62
68	A multicenter experience on the prevalence of ARMC5 mutations in patients with primary bilateral macronodular adrenal hyperplasia: from genetic characterization to clinical phenotype. <i>Endocrine</i> , 2017, 55, 959-968.	1.1	62
69	Personality characteristics and quality of life in patients treated for Cushing's syndrome. <i>Clinical Endocrinology</i> , 2006, 64, 314-318.	1.2	60
70	Harmful effects of functional hypercortisolism: a working hypothesis. <i>Endocrine</i> , 2014, 46, 370-386.	1.1	60
71	Investigations on the Morphology and Function of Adrenocortical Tissue Regenerated from Gland Capsular Fragments Autotransplanted in the Musculus Gracilis of the Rat. <i>Endocrinology</i> , 1990, 126, 3251-3262.	1.4	57
72	Age-Related Changes in Glucocorticoid Fast Feedback Inhibition of Adrenocorticotropin in Man. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 1380-1383.	1.8	57

#	ARTICLE	IF	CITATIONS
73	P450c17 Deficiency: Clinical and Molecular Characterization of Six Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1000-1007.	1.8	57
74	Systematic review of surgical treatment of subclinical Cushing's syndrome. <i>British Journal of Surgery</i> , 2015, 102, 318-330.	0.1	57
75	Screening Tests for Cushing's Syndrome: Urinary Free Cortisol Role Measured by LC-MS/MS. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3856-3861.	1.8	56
76	Managing Cushing's disease: the state of the art. <i>Endocrine</i> , 2014, 47, 9-20.	1.1	54
77	A role for life events in the pathogenesis of Cushing's disease. <i>Clinical Endocrinology</i> , 1993, 38, 261-264.	1.2	53
78	Self image and quality of life in acromegaly. <i>Pituitary</i> , 2002, 5, 17-19.	1.6	52
79	The ENDOTRIAL Study: A Spontaneous, Open-Label, Randomized, Multicenter, Crossover Study on the Efficacy of Sildenafil, Tadalafil, and Vardenafil in the Treatment of Erectile Dysfunction. <i>Journal of Sexual Medicine</i> , 2009, 6, 2547-2560.	0.3	52
80	Coagulopathy in Cushing's Syndrome. <i>Neuroendocrinology</i> , 2010, 92, 55-59.	1.2	52
81	Second-line tests in the differential diagnosis of ACTH-dependent Cushing's syndrome. <i>Pituitary</i> , 2016, 19, 488-495.	1.6	52
82	A Clinical Index for Rating Severity in Cushing's Syndrome. <i>Psychotherapy and Psychosomatics</i> , 2000, 69, 216-220.	4.0	51
83	Evaluation and diagnostic potential of circulating extracellular vesicle-associated microRNAs in adrenocortical tumors. <i>Scientific Reports</i> , 2017, 7, 5474.	1.6	51
84	Coenzyme Q10 and male infertility. <i>Journal of Endocrinological Investigation</i> , 2009, 32, 626-632.	1.8	50
85	Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center. <i>Journal of Neuro-Oncology</i> , 2015, 122, 189-196.	1.4	50
86	Hormonal responses during various phases of autoimmune adrenal failure: no evidence for 21-hydroxylase enzyme activity inhibition in vivo.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 2801-2804.	1.8	49
87	Clinical and molecular study in congenital muscular dystrophy with partial laminin $\alpha$ 2 (LAMA2) deficiency. <i>Human Mutation</i> , 2003, 21, 103-111.	1.1	49
88	Left ventricular structural characteristics in Cushing's syndrome. <i>Journal of Human Hypertension</i> , 1994, 8, 509-13.	1.0	49
89	Psychosocial impairment in patients treated for pituitary disease: a controlled study. <i>Clinical Endocrinology</i> , 2007, 67, 719-726.	1.2	48
90	Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas. <i>BMC Endocrine Disorders</i> , 2010, 10, 10.	0.9	48

#	ARTICLE	IF	CITATIONS
91	Testosterone and cardiovascular risk. <i>Internal and Emergency Medicine</i> , 2013, 8, 65-69.	1.0	48
92	Cushing's Syndrome: Screening and Diagnosis. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2016, 23, 209-215.	1.0	48
93	Correlates of perceived health related quality of life in obese, overweight and normal weight older adults: an observational study. <i>BMC Public Health</i> , 2014, 14, 35.	1.2	47
94	The production of peroxynitrite by human spermatozoa may affect sperm motility through the formation of protein nitrotyrosine. <i>Fertility and Sterility</i> , 2006, 85, 947-953.	0.5	46
95	Association of glucocorticoid receptor polymorphism A3669G with decreased risk of developing diabetes in patients with Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2012, 166, 35-42.	1.9	46
96	Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial. <i>Pituitary</i> , 2015, 18, 604-612.	1.6	46
97	Life events in the pathogenesis of hyperprolactinemia. <i>European Journal of Endocrinology</i> , 2004, 151, 61-65.	1.9	45
98	Analysis of the 11 $\beta$ -Hydroxysteroid Dehydrogenase Type 2 Gene (HSD11B2) in Human Essential Hypertension. <i>American Journal of Hypertension</i> , 2005, 18, 1091-1098.	1.0	45
99	Effect of natural early menopause on bone mineral density. <i>Maturitas</i> , 2008, 59, 323-328.	1.0	45
100	Perioperative thromboprophylaxis in Cushing's disease: What we did and what we are doing?. <i>Pituitary</i> , 2015, 18, 487-493.	1.6	45
101	Effect of Angiotensin II and Converting Enzyme Inhibitor (Captopril) on Blood Pressure, Plasma Renin Activity and Aldosterone in Primary Aldosteronism. <i>Clinical Science</i> , 1981, 61, 289s-293s.	0.0	44
102	Acute and chronic effects of high glucocorticoid levels on hypothalamic-pituitary-thyroid axis in man. <i>Journal of Endocrinological Investigation</i> , 1992, 15, 437-441.	1.8	44
103	Adipose Tissue as an Endocrine Organ? A Review of Recent Data Related to Cardiovascular Complications of Endocrine Dysfunctions. <i>Clinical and Experimental Hypertension</i> , 2004, 26, 387-398.	0.5	44
104	Bone complications in patients with Cushing's syndrome: looking for clinical, biochemical, and genetic determinants. <i>Osteoporosis International</i> , 2014, 25, 913-921.	1.3	44
105	Metyrapone treatment in Cushing's syndrome: a real-life study. <i>Endocrine</i> , 2018, 62, 701-711.	1.1	44
106	Age-Related Changes in Glucocorticoid Fast Feedback Inhibition of Adrenocorticotropin in Man. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 1380-1383.	1.8	44
107	Effect of surgical treatment on hypertension in Cushing's syndrome. <i>American Journal of Hypertension</i> , 1996, 9, 77-80.	1.0	43
108	Hormonal responses during various phases of autoimmune adrenal failure: no evidence for 21-hydroxylase enzyme activity inhibition in vivo. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 2801-2804.	1.8	43

#	ARTICLE	IF	CITATIONS
109	Extended treatment of Cushing's disease with pasireotide: results from a 2-year, Phase II study. <i>Pituitary</i> , 2014, 17, 320-326.	1.6	42
110	Response of hypertension to conventional antihypertensive treatment and/or steroidogenesis inhibitors in Cushing's syndrome. <i>Journal of Internal Medicine</i> , 1993, 234, 595-598.	2.7	41
111	Estrogen and thyroid cancer is a stem affair: A preliminary study. <i>Biomedicine and Pharmacotherapy</i> , 2017, 85, 399-411.	2.5	41
112	RESPONSE OF PITUITARY-ADRENAL AXIS TO CORTICOTROPHIN RELEASING HORMONE IN PATIENTS WITH CUSHING'S DISEASE BEFORE AND AFTER KETOCONAZOLE TREATMENT. <i>Clinical Endocrinology</i> , 1987, 27, 461-467.	1.2	40
113	Effect of the serotonin antagonists ritanserin and ketanserin in Cushing's disease. <i>Pituitary</i> , 2000, 3, 55-59.	1.6	40
114	Genetic Alterations in Medullary Thyroid Cancer: Diagnostic and Prognostic Markers. <i>Current Genomics</i> , 2011, 12, 618-625.	0.7	40
115	MULTIPLE ENDOCRINE NEOPLASIA TYPE 1 AND ADRENAL LESIONS. <i>Journal of Urology</i> , 2001, 166, 24-27.	0.2	39
116	Visceral adipose tissue: emerging role of glucose and mineralocorticoid hormones in the setting of cardiometabolic alterations. <i>Annals of the New York Academy of Sciences</i> , 2012, 1264, 87-102.	1.8	39
117	EFFECT OF BROMOCRIPTINE IN PITUITARY-DEPENDENT CUSHING'S SYNDROME. <i>Clinical Endocrinology</i> , 1983, 19, 485-491.	1.2	38
118	Gene therapy of thyroid cancer via retrovirally-driven combined expression of human interleukin-2 and herpes simplex virus thymidine kinase. <i>European Journal of Endocrinology</i> , 2003, 148, 73-80.	1.9	38
119	Primary aldosteronism, a major form of low renin hypertension: from screening to diagnosis. <i>Trends in Endocrinology and Metabolism</i> , 2008, 19, 104-108.	3.1	38
120	Free thiols in human spermatozoa: are Na <sup>+</sup> /K <sup>+</sup> -ATPase, Ca <sup>2+</sup> -ATPase activities involved in sperm motility through peroxynitrite formation?. <i>Reproductive BioMedicine Online</i> , 2009, 18, 132-140.	1.1	38
121	Human corticotropin releasing hormone test performance in the differential diagnosis between Cushing's disease and pseudo-Cushing state is enhanced by combined ACTH and cortisol analysis. <i>European Journal of Endocrinology</i> , 2009, 160, 891-898.	1.9	38
122	Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor. <i>Clinical Endocrinology</i> , 2003, 59, 328-338.	1.2	37
123	Corticotrophin-releasing hormone and desmopressin tests in the differential diagnosis between Cushing's disease and pseudo-Cushing state: a comparative study. <i>Clinical Endocrinology</i> , 2011, 75, 666-672.	1.2	37
124	Role of bilateral adrenalectomy in Cushing's disease. <i>World Journal of Surgery</i> , 1994, 18, 462-466.	0.8	36
125	Evaluation of circulating thyroid-specific transcripts as markers of thyroid cancer relapse. <i>International Journal of Cancer</i> , 2004, 110, 914-920.	2.3	36
126	Metabolic syndrome in primary aldosteronism and essential hypertension: Relationship to adiponectin gene variants. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2010, 20, 93-100.	1.1	36



#	ARTICLE	IF	CITATIONS
127	Long-term glucocorticoid effect on bone mineral density in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. <i>European Journal of Endocrinology</i> , 2016, 175, 101-106.	1.9	36
128	Recovery of Bone Mineral Density after Surgical Cure, but not by Ketoconazole Treatment, in Cushing's Syndrome. <i>Osteoporosis International</i> , 2001, 12, 956-960.	1.3	35
129	Transcriptionally Targeted Retroviral Vector for Combined Suicide and Immunomodulating Gene Therapy of Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 5304-5311.	1.8	35
130	A venous thromboembolism risk assessment model for patients with Cushing's syndrome. <i>Endocrine</i> , 2016, 52, 322-332.	1.1	35
131	Isolation and characterization of progenitor mesenchymal cells in human pituitary tumors. <i>Cancer Gene Therapy</i> , 2015, 22, 9-16.	2.2	34
132	Pharmacologic Management of Cushing Syndrome. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2005, 4, 87-94.	1.8	33
133	Oleylethanolamide Protects Human Sperm Cells from Oxidation Stress: Studies on Cases of Idiopathic Infertility. <i>Biology of Reproduction</i> , 2006, 74, 659-665.	1.2	33
134	OBESITY AND BODY MASS INDEX (BMI) IN RELATION TO LIFE-STYLE AND PSYCHO-SOCIAL ASPECTS. <i>Archives of Gerontology and Geriatrics</i> , 2009, 49, 195-206.	1.4	33
135	The medical treatment with pasireotide in Cushing's disease: an Italian multicentre experience based on a real-world evidence. <i>Endocrine</i> , 2019, 64, 657-672.	1.1	33
136	24-Hour Blood Pressure Profile in Addison's Disease. <i>American Journal of Hypertension</i> , 1994, 7, 1105-1109.	1.0	32
137	Slow-Release Lanreotide Treatment in Acromegaly: Effects on Quality of Life. <i>Psychotherapy and Psychosomatics</i> , 1999, 68, 165-167.	4.0	32
138	Vascular Endothelial Growth Factor and Microvessel Density in Periodontitis Patients With and Without Diabetes. <i>Journal of Periodontology</i> , 2009, 80, 1783-1789.	1.7	32
139	Diabetes mellitus-associated periodontitis: differences between type 1 and type 2 diabetes mellitus. <i>Journal of Periodontal Research</i> , 2011, 46, 164-169.	1.4	32
140	Daily salivary cortisol and cortisone rhythm in patients with adrenal incidentaloma. <i>Endocrine</i> , 2018, 59, 510-519.	1.1	32
141	STRESSFUL LIFE EVENTS IN THE PATHOGENESIS OF CUSHING'S SYNDROME. <i>Clinical Endocrinology</i> , 1988, 29, 617-623.	1.2	30
142	Reduced nitric oxide levels in acromegaly: cardiovascular implications. <i>Blood Pressure</i> , 2005, 14, 227-232.	0.7	30
143	First-line screening tests for Cushing's syndrome in patients with adrenal incidentaloma: the role of urinary free cortisol measured by LC-MS/MS. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 753-760.	1.8	30
144	Effect of serotonin on plasma aldosterone in man. <i>Journal of Endocrinological Investigation</i> , 1982, 5, 97-99.	1.8	29

#	ARTICLE	IF	CITATIONS
145	Evidence for Ultra-Short Loop Autoregulation of Adrenocorticotropin Secretion in Man. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1988, 66, 255-257.	1.8	28
146	Paclitaxel Is an Effective Antiproliferative Agent on the Human NCI-H295 Adrenocortical Carcinoma Cell Line. <i>Chemotherapy</i> , 1998, 44, 129-134.	0.8	28
147	Adrenal incidentaloma: Surgical update. <i>Journal of Endocrinological Investigation</i> , 2007, 30, 200-204.	1.8	28
148	Sexual Dysfunctions in Men Affected by Autoimmune Addison's Disease Before and After Short-Term Gluco- and Mineralocorticoid Replacement Therapy. <i>Journal of Sexual Medicine</i> , 2013, 10, 2036-2043.	0.3	28
149	25-Hydroxycholecalciferol response to single oral cholecalciferol loading in the normal weight, overweight, and obese. <i>Osteoporosis International</i> , 2016, 27, 2593-2602.	1.3	28
150	Selective Venous Sampling in the Differential Diagnosis of ACTH-Dependent Cushing's Syndrome. <i>Neuroendocrinology</i> , 1992, 55, 264-268.	1.2	27
151	Early adrenal hypofunction in patients with organ-specific autoantibodies and no clinical adrenal insufficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994, 79, 452-455.	1.8	27
152	Coexistence of Aldosteronoma and Contralateral Nonfunctioning Adrenal Adenoma in Primary Aldosteronism. <i>American Journal of Hypertension</i> , 1997, 10, 476-478.	1.0	27
153	A New Germline Point Mutation in Ret Exon 8 (Cys <sup>515</sup> Ser) in a Family with Medullary Thyroid Carcinoma. <i>Thyroid</i> , 2008, 18, 775-782.	2.4	27
154	Have androgen receptor gene CAG and GGC repeat polymorphisms an effect on sperm motility in infertile men?. <i>Andrologia</i> , 2014, 46, 564-569.	1.0	27
155	Anaplastic Thyroid Carcinoma. <i>Frontiers in Endocrinology</i> , 2012, 3, 84.	1.5	26
156	A Single-Center 10-Year Experience with Pasireotide in Cushing's Disease: Patients' Characteristics and Outcome. <i>Hormone and Metabolic Research</i> , 2016, 48, 290-298.	0.7	26
157	Plasma Renin Activity and Urinary Aldosterone in Cushing's Syndrome. <i>Hormone and Metabolic Research</i> , 1978, 10, 65-71.	0.7	25
158	Progesterone increase counteracts aldosterone action in a pregnant woman with primary aldosteronism. <i>Clinical Endocrinology</i> , 2011, 74, 278-279.	1.2	25
159	Primary aldosteronism and essential hypertension: Assessment of cardiovascular risk at diagnosis and after treatment. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 476-482.	1.1	25
160	Up-to 5-year efficacy of pasireotide in a patient with Cushing's disease and pre-existing diabetes: literature review and clinical practice considerations. <i>Pituitary</i> , 2015, 18, 359-365.	1.6	25
161	An in vitro stimulatory effect of indoleamines on aldosterone biosynthesis in the rat. <i>The Journal of Steroid Biochemistry</i> , 1982, 17, 351-355.	1.3	24
162	Endocrine Aspects of Cancer Gene Therapy. <i>Endocrine Reviews</i> , 2004, 25, 1-44.	8.9	24

#	ARTICLE	IF	CITATIONS
163	Chemical-physical properties of lipoproteins in anorexia nervosa. <i>European Journal of Clinical Investigation</i> , 2004, 34, 747-751.	1.7	24
164	Protective effect of leg fat against cardiovascular risk factors in obese premenopausal women. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2009, 19, 39-44.	1.1	24
165	Primary adrenal hypercortisolism: minimally invasive surgical treatment or medical therapy? A retrospective study with long-term follow-up evaluation. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2010, 24, 2542-2546.	1.3	24
166	Improved salivary cortisol rhythm with dual-release hydrocortisone. <i>Endocrine Connections</i> , 2018, 7, 965-974.	0.8	24
167	Diagnosis and management of adrenal incidentalomas. <i>Journal of Urology</i> , 2000, 163, 398-407.	0.2	24
168	New perspectives for gene therapy in endocrinology. <i>European Journal of Endocrinology</i> , 2000, 143, 447-466.	1.9	23
169	Synergistic antitumour activity of <sc>RAF</sc>265 and <sc>ZSTK</sc>474 on human <sc>TT</sc> medullary thyroid cancer cells. <i>Journal of Cellular and Molecular Medicine</i> , 2015, 19, 2244-2252.	1.6	23
170	HypoparaNet: A Database of Chronic Hypoparathyroidism Based on Expert Medical-Surgical Centers in Italy. <i>Calcified Tissue International</i> , 2018, 103, 151-163.	1.5	23
171	A constitutive active MAPK/ERK pathway due to BRAFV600E positively regulates AHR pathway in PTC. <i>Oncotarget</i> , 2015, 6, 32104-32114.	0.8	23
172	Adipose cell-adrenal interactions: current knowledge and future perspectives. <i>Trends in Endocrinology and Metabolism</i> , 2008, 19, 100-103.	3.1	22
173	Small tumor size as favorable prognostic factor after adrenalectomy in Conn's adenoma. <i>European Journal of Endocrinology</i> , 2009, 160, 639-646.	1.9	22
174	Aldosterone, Mineralocorticoid Receptor and the Metabolic Syndrome: Role of the Mineralocorticoid Receptor Antagonists. <i>Current Vascular Pharmacology</i> , 2012, 10, 238-246.	0.8	22
175	The combination of RAF265, SB590885, ZSTK474 on thyroid cancer cell lines deeply impact on proliferation and MAPK and PI3K/Akt signaling pathways. <i>Investigational New Drugs</i> , 2014, 32, 626-635.	1.2	22
176	Clinical use of pasireotide for Cushing's disease in adults. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 425.	0.9	22
177	Analysis of circulating extracellular vesicle-associated microRNAs in cortisol-producing adrenocortical tumors. <i>Endocrine</i> , 2018, 59, 280-287.	1.1	22
178	Vertebral fractures assessed with dual-energy X-ray absorptiometry in patients with Addison's disease on glucocorticoid and mineralocorticoid replacement therapy. <i>Endocrine</i> , 2018, 59, 319-329.	1.1	22
179	Human Corticotropin-Releasing Hormone Tests: 10 Years of Real-Life Experience in Pituitary and Adrenal Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3938-e3949.	1.8	22
180	Increased factor VIII associated activities in Cushing's syndrome: a probable hypercoagulable state. <i>Thrombosis and Haemostasis</i> , 1982, 47, 116-7.	1.8	22

#	ARTICLE	IF	CITATIONS
181	Inhibitory effect of somatostatin on the aldosterone response to angiotensin II: in vitro studies. <i>Journal of Endocrinological Investigation</i> , 1982, 5, 173-177.	1.8	21
182	Idiopathic Infertility: Effect of Palmitoylethanolamide (a Homologue of Anandamide) on Hyperactivated Sperm Cell Motility and Ca <sup>2+</sup> Influx. <i>Journal of Andrology</i> , 2005, 26, 429-436.	2.0	21
183	Further studies on the hypercoagulable state of patients with Cushing's syndrome. <i>Thrombosis and Haemostasis</i> , 1985, 54, 518-20.	1.8	21
184	Effect of Metoclopramide on Plasma Aldosterone in Normal Subjects, Primary Aldosteronism and Hypopituitarism. <i>Hormone and Metabolic Research</i> , 1981, 13, 464-467.	0.7	20
185	Regression of cardiac abnormalities after replacement therapy in Addison's disease. <i>European Journal of Endocrinology</i> , 1999, 140, 425-428.	1.9	20
186	Idiopathic infertility: susceptibility of spermatozoa to in-vitro capacitation, in the presence and the absence of palmitylethanolamide (a homologue of anandamide), is strongly correlated with membrane polarity studied by Laurdan fluorescence. <i>Molecular Human Reproduction</i> , 2003, 9, 381-388.	1.3	20
187	Salivary cortisol is a useful tool to assess the early response to pasireotide in patients with Cushing's disease. <i>Pituitary</i> , 2015, 18, 60-67.	1.6	20
188	Plasma renin activity and urinary aldosterone in acromegaly. <i>Journal of Endocrinological Investigation</i> , 1979, 2, 13-18.	1.8	19
189	In Situ Analysis of Human Menin in Normal and Neoplastic Pancreatic Tissues: Evidence for Differential Expression in Exocrine and Endocrine Cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 3893-3901.	1.8	19
190	Diagnostic accuracy of increased urinary cortisol/cortisone ratio to differentiate ACTH-dependent Cushing's syndrome. <i>Clinical Endocrinology</i> , 2017, 87, 500-507.	1.2	19
191	Crude extract of <i>Origanum vulgare</i> L. induced cell death and suppressed MAPK and PI3/Akt signaling pathways in SW13 and H295R cell lines. <i>Natural Product Research</i> , 2019, 33, 1646-1649.	1.0	19
192	Adrenal morpho-functional alterations in patients with acromegaly. <i>Journal of Endocrinological Investigation</i> , 2008, 31, 602-606.	1.8	18
193	Pasireotide for the treatment of Cushing's disease. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 889-898.	1.9	18
194	Management of Primary Aldosteronism: Its Complications and Their Outcomes After Treatment. <i>Current Vascular Pharmacology</i> , 2009, 7, 244-249.	0.8	18
195	Corticotropin releasing hormone stimulation test: diagnostic aspects in Cushing's syndrome. <i>Journal of Endocrinological Investigation</i> , 1987, 10, 297-302.	1.8	17
196	Steroids and hypertension. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1991, 40, 35-44.	1.2	17
197	Overnight dexamethasone suppression of cortisol is associated with radiocholesterol uptake patterns in adrenal incidentalomas. <i>European Journal of Endocrinology</i> , 2001, 145, 223-224.	1.9	17
198	Early adrenal hypofunction in patients with organ-specific autoantibodies and no clinical adrenal insufficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994, 79, 452-455.	1.8	17

#	ARTICLE	IF	CITATIONS
199	Psychological Distress and Quality of Life in Endocrine Disease. <i>Psychotherapy and Psychosomatics</i> , 1990, 54, 140-144.	4.0	16
200	Low-dose ketoconazole treatment in hirsute women. <i>Journal of Endocrinological Investigation</i> , 1990, 13, 35-40.	1.8	16
201	A Pilot Study of Combined Suicide/Cytokine Gene Therapy in Two Patients with End-Stage Anaplastic Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 2831-2834.	1.8	16
202	Role of raloxifene on platelet metabolism and plasma lipids. <i>European Journal of Clinical Investigation</i> , 2008, 38, 117-125.	1.7	16
203	Diagnosis and management of primary aldosteronism. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2008, 15, 332-338.	1.2	16
204	New Insight into the Hypercoagulability of Cushing's Syndrome. <i>Neuroendocrinology</i> , 2011, 93, 121-125.	1.2	16
205	Spironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI. <i>Journal of Endocrinological Investigation</i> , 2016, 39, 1015-1021.	1.8	16
206	Pasireotide treatment reduces cardiometabolic risk in Cushing's disease patients: an Italian, multicenter study. <i>Endocrine</i> , 2018, 61, 118-124.	1.1	16
207	Secondary Arterial Hypertension: From Routine Clinical Practice to Evidence in Patients with Adrenal Tumor. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2018, 25, 345-354.	1.0	16
208	Defects of steroidogenesis. <i>Journal of Endocrinological Investigation</i> , 2010, 33, 756-766.	1.8	15
209	Evaluation of angiotensin type 1 receptor antibodies in primary aldosteronism and further considerations about their possible pathogenetic role. <i>Journal of Clinical Hypertension</i> , 2018, 20, 1313-1318.	1.0	15
210	A multidisciplinary approach to the management of adrenal incidentaloma. <i>Expert Review of Endocrinology and Metabolism</i> , 2021, 16, 201-212.	1.2	15
211	Indication to dynamic and invasive testing in Cushing's disease according to different neuroradiological findings. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 629-637.	1.8	15
212	Increased factor VIII/vWf levels in patients with reduced platelet number. <i>Blut</i> , 1987, 54, 281-288.	1.2	14
213	Corticotropin-Releasing Effect of Hexarelin, a Peptidyl GH Secretagogue, in Normal Subjects Pretreated with Metyrapone or RU-486, a Glucocorticoid Receptor Antagonist, and in Patients with Addison's Disease. <i>Neuroendocrinology</i> , 1999, 70, 200-206.	1.2	14
214	Diagnosis of co-morbid axis-I psychiatric disorders among women with newly diagnosed, untreated endocrine disorders. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 991-996.	1.3	14
215	Blood Pressure, Thyroid-Stimulating Hormone, and Thyroid Disease Prevalence in Primary Aldosteronism and Essential Hypertension. <i>American Journal of Hypertension</i> , 2011, 24, 1274-1279.	1.0	14
216	Investigation of N-cadherin/ $\beta$ -catenin expression in adrenocortical tumors. <i>Tumor Biology</i> , 2016, 37, 13545-13555.	0.8	14

#	ARTICLE	IF	CITATIONS
217	Frequently asked questions and answers (if any) in patients with adrenal incidentaloma. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 2749-2763.	1.8	14
218	Type I and type II disease in congenital factor XIII deficiency. <i>Blut</i> , 1986, 53, 411-413.	1.2	13
219	Effect of Naloxone on the Adrenal Cortex in Primary Aldosteronism. <i>American Journal of Hypertension</i> , 1988, 1, 280-282.	1.0	13
220	Effects of prolonged sodium restriction on the morphology and function of rat adrenocortical autotransplants. <i>Cell and Tissue Research</i> , 1991, 265, 35-41.	1.5	13
221	Effect of Octreotide on 24-h Blood Pressure Profile in Acromegaly. <i>American Journal of Hypertension</i> , 1998, 11, 591-596.	1.0	13
222	Expression of growth hormone-releasing hormone receptor splicing variants in human primary adrenocortical tumours. <i>Clinical Endocrinology</i> , 2005, 62, 533-538.	1.2	13
223	Age and the metabolic syndrome affect salivary cortisol rhythm: data from a community sample. <i>Hormones</i> , 2015, 14, 392-8.	0.9	13
224	The aurora kinase inhibitor VX-680 shows anti-cancer effects in primary metastatic cells and the SW13 cell line. <i>Investigational New Drugs</i> , 2016, 34, 531-540.	1.2	13
225	Dexamethasone-suppressible hyperaldosteronism: Pathophysiology, clinical aspects, and new insights into the pathogenesis. <i>Klinische Wochenschrift</i> , 1987, 65, 437-444.	0.6	12
226	Inhibition of Pituitary $\hat{2}$ -Endorphin by ACTH and Glucocorticoids. <i>Neuroendocrinology</i> , 1990, 51, 561-564.	1.2	12
227	New Aspects of Mineralocorticoid Hypertension. <i>Hormone Research</i> , 1990, 34, 175-180.	1.8	12
228	Disseminated nocardiosis in a patient with Cushing's syndrome. <i>Journal of Endocrinological Investigation</i> , 1994, 17, 443-445.	1.8	12
229	Gene therapy for thyroid cancer. <i>Expert Opinion on Biological Therapy</i> , 2004, 4, 1225-1239.	1.4	12
230	The role of an acute pasireotide suppression test in predicting response to treatment in patients with Cushing's disease: findings from a pilot study. <i>Endocrine</i> , 2015, 50, 154-161.	1.1	12
231	GSTM1 and CYP2D6 genotype frequencies in patients with pituitary tumours: effects on P53, ras and gsp. <i>Carcinogenesis</i> , 1995, 16, 1643-1645.	1.3	11
232	Metabolic syndrome does not increase angiographic restenosis rates after drug-eluting stent implantation. <i>Metabolism: Clinical and Experimental</i> , 2008, 57, 593-597.	1.5	11
233	Fine-needle aspiration cytology of adrenal masses: a re-assessment with histological confirmation. <i>Journal of Endocrinological Investigation</i> , 2012, 35, 590-4.	1.8	11
234	Intrapituitary cytokines in Cushing's disease: do they play a role?. <i>Pituitary</i> , 2011, 14, 236-241.	1.6	10

#	ARTICLE	IF	CITATIONS
235	Increase in vascular permeability produced in rat airways by PAF: potentiation by adrenalectomy. <i>British Journal of Pharmacology</i> , 1992, 105, 388-392.	2.7	9
236	Percutaneous Therapy of Varicocele: Effects on Semen Parameters in Young Adults. <i>Urologia Internationalis</i> , 2004, 72, 150-153.	0.6	9
237	Vitamin D levels and bone mineral density: are LH levels involved in the pathogenesis of bone impairment in hypogonadal men?. <i>Journal of Endocrinological Investigation</i> , 2014, 37, 1225-1231.	1.8	9
238	Association of primary aldosteronism with chronic thyroiditis. <i>Endocrine</i> , 2017, 55, 303-306.	1.1	9
239	Decrease in salivary cortisol levels after glucocorticoid dose reduction in patients with adrenal insufficiency: A prospective proof-of-concept study. <i>Clinical Endocrinology</i> , 2018, 88, 201-208.	1.2	9
240	Circadian Secretion of Acth, Cortisol, and Mineralocorticoids in Cushing's Syndrome. <i>Clinical and Experimental Hypertension</i> , 1982, 4, 1779-1794.	0.3	8
241	Adrenal Scintigraphy in the Morphological and Functional Evaluation of Cushing's Syndrome. <i>Cardiology</i> , 1985, 72, 76-83.	0.6	8
242	Evidence for ectopic ACTH production years after bilateral adrenalectomy for Cushing's syndrome: in vivo and in vitro studies. <i>Journal of Endocrinological Investigation</i> , 1985, 8, 417-421.	1.8	8
243	Effect of $\pm$ -Human Atrial Natriuretic Peptide in Low Renin Essential Hypertension and Primary Aldosteronism. <i>Clinical and Experimental Hypertension</i> , 1987, 9, 1505-1513.	0.3	8
244	Fibrinolysis and coagulation abnormalities in systemic lupus erythematosus. <i>Rheumatology International</i> , 1995, 14, 207-211.	1.5	8
245	Modulation of retrovirally driven therapeutic genes by mutant TP53 in anaplastic thyroid carcinoma. <i>Cancer Gene Therapy</i> , 2005, 12, 381-388.	2.2	8
246	Aldosterone, Calcium, and Hypertension. <i>American Journal of Nephrology</i> , 1986, 6, 33-39.	1.4	7
247	Atrial natriuretic peptide in Cushing's disease. <i>Journal of Endocrinological Investigation</i> , 1990, 13, 133-137.	1.8	7
248	Patterns of ACTH Response to oCRH in Cushing's Disease: Correlation with Histological/Immunocytochemical Findings. <i>Neuroendocrinology</i> , 1994, 60, 237-242.	1.2	7
249	New treatment guidelines on Cushing's disease. <i>F1000 Medicine Reports</i> , 2009, 1, .	2.9	7
250	Fracture risk assessment before and after resolution of endogenous hypercortisolism: Is the FRAX® algorithm useful?. <i>Journal of Endocrinological Investigation</i> , 2014, 37, 957-965.	1.8	7
251	Effect of a single injection of testosterone enanthate on $17\beta$ estradiol and bone turnover markers in hypogonadal male patients. <i>Journal of Endocrinological Investigation</i> , 2015, 38, 389-397.	1.8	7
252	New insights to the potential mechanisms driving coronary flow reserve impairment in Cushing's syndrome: A pilot noninvasive study by transthoracic Doppler echocardiography. <i>Microvascular Research</i> , 2020, 128, 103940.	1.1	7

#	ARTICLE	IF	CITATIONS
253	Growth hormone deficiency in the transition period: body composition and gonad function. Journal of Endocrinological Investigation, 2011, 34, 709-15.	1.8	7
254	Adrenocortical carcinoma: epidemiology and natural history. Minerva Endocrinologica, 1995, 20, 89-94.	1.7	7
255	Lipoproteins Obtained from Anorexia Nervosa Patients Induce Higher Oxidative Stress in U373MG Astrocytes Through Nitric Oxide Production. NeuroMolecular Medicine, 2008, 10, 17-23.	1.8	6
256	Cortical adrenal mitochondrial morphology changes in functional state: new insights. Cell and Tissue Research, 2013, 351, 409-417.	1.5	6
257	Mitogen-Activated Protein Kinase Pathway: Genetic Analysis of 95 Adrenocortical Tumors. Cancer Investigation, 2015, 33, 526-531.	0.6	6
258	Medical Treatment for Acromegaly does not Increase the Risk of Central Adrenal Insufficiency: A Long-Term Follow-Up Study. Hormone and Metabolic Research, 2016, 48, 514-519.	0.7	6
259	Body Composition is Different After Surgical or Pharmacological Remission of Cushing's Syndrome: A Prospective DXA Study. Hormone and Metabolic Research, 2017, 49, 660-666.	0.7	6
260	Effect of short and long-term administration of lisuride in Cushing's disease. Journal of Endocrinological Investigation, 1985, 8, 13-17.	1.8	5
261	Raloxifene and Cardiovascular Health: Its Relationship to Lipid and Glucose Metabolism, Hemostatic and Inflammation Factors and Cardiovascular Function in Postmenopausal Women. Current Pharmaceutical Design, 2005, 11, 4187-4206.	0.9	5
262	Human leucocytes in asthenozoospermic patients: endothelial nitric oxide synthase expression. Andrologia, 2014, 46, 1176-1182.	1.0	5
263	EFFECTS OF NALOXONE ON THE PITUITARY-ADRENAL AXIS IN PATIENTS WITH DEXAMETHASONE-SUPPRESSIBLE HYPERALDOSTERONISM. Clinical Endocrinology, 1987, 26, 163-168.	1.2	4
264	Advances in medical treatment of Cushing's disease. Expert Review of Endocrinology and Metabolism, 2007, 2, 735-743.	1.2	4
265	The role of psychological well-being in obese and overweight older adults. International Psychogeriatrics, 2016, 28, 171-172.	0.6	4
266	Cardiovascular autonomic dysfunction in patients with idiopathic diabetes insipidus. Pituitary, 2018, 21, 50-55.	1.6	4
267	Low-dose short synacthen test with salivary cortisol in patients with suspected central adrenal insufficiency. Endocrine Connections, 2021, 10, 1189-1199.	0.8	4
268	DIAGNOSIS AND MANAGEMENT OF ADRENAL INCIDENTALOMAS. Journal of Urology, 2000, , 398.	0.2	4
269	Effect of a Synthetic Substituted $\pm$ 1-18 ACTH on Mineralocorticoid Secretion. Hormone and Metabolic Research, 1980, 12, 464-470.	0.7	3
270	Effect of metergoline on the aldosterone-stimulating properties of metoclopramide. The Journal of Steroid Biochemistry, 1983, 19, 531-536.	1.3	3



#	ARTICLE	IF	CITATIONS
271	Serum levels of calcitonin in Cushing's syndrome. Journal of Endocrinological Investigation, 1986, 9, 239-241.	1.8	3
272	Effects of naloxone on adrenal cortex regulation in patients with primary aldosteronism. Journal of Endocrinological Investigation, 1988, 11, 261-265.	1.8	3
273	Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism. Journal of Hypertension, 2006, 24, 1899-1900.	0.3	3
274	Evaluation and implications of salt intake and excretion. Journal of Clinical Hypertension, 2019, 21, 950-952.	1.0	3
275	Alpha-1 adrenergic blockade: a possible mechanism of action of dopaminergic drugs on ACTH secretion. Journal of Endocrinological Investigation, 1985, 8, 523-526.	1.8	2
276	Factor XII activation after DDAVP. Thrombosis Research, 1990, 58, 531-532.	0.8	2
277	Clinical Symposium. Journal of Endocrinological Investigation, 1992, 15, 223-244.	1.8	2
278	Hypogonadism and Reduced Bone Mineral Density in Heterozygous H63D Mutation in the HFE Gene: An Unusual Presentation of Hereditary Hemochromatosis. Journal of Andrology, 2006, 28, 21-26.	2.0	2
279	The Prevalence of HTLV-III and HTLV-I Antibodies in Serum of Hemophiliacs. Thrombosis and Haemostasis, 1985, 54, 897-897.	1.8	2
280	Is this a seizure?. Clinical Cases in Mineral and Bone Metabolism, 2017, 14, 89.	1.0	2
281	Potential therapeutic effects of ritanserin in Cushing's disease. JAMA - Journal of the American Medical Association, 1992, 267, 1073.	3.8	2
282	Pituitary microadenomas: Surgical results and morphological findings. Acta Neurochirurgica, 1983, 69, 231-242.	0.9	1
283	Pro-gamma-MSH levels in various disorders of pituitary-adrenal axis. Journal of Endocrinological Investigation, 1990, 13, 29-33.	1.8	1
284	Gene therapy for thyroid cancer. Expert Review of Endocrinology and Metabolism, 2006, 1, 367-378.	1.2	1
285	Pituitary-directed medical treatment of Cushing's disease. Expert Review of Endocrinology and Metabolism, 2009, 4, 263-272.	1.2	1
286	Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. European Journal of Endocrinology, 2010, 163, 963.	1.9	1
287	Hypertension in Cushing's Syndrome. Updates in Hypertension and Cardiovascular Protection, 2020, , 127-139.	0.1	1
288	Unilateral primary aldosteronism considerations about the diagnostic criteria, adrenalectomy, and short and long time biochemical and clinical evaluation. Journal of Clinical Hypertension, 2022, 24, 116-118.	1.0	1

#	ARTICLE	IF	CITATIONS
289	Possible efficacy of Lavender and Tea tree oils in the treatment of young women affected by mild idiopathic hirsutism. Journal of Endocrinological Investigation, 2013, 36, 50-4.	1.8	1
290	217. Effect of metoclopramide on plasma aldosterone: in vivo and in vitro studies. The Journal of Steroid Biochemistry, 1978, 9, 858.	1.3	0
291	Diagnosi della sindrome di Cushing. L Endocrinologo, 2005, 6, 137-142.	0.0	0
292	Ipo- e iperpotassiemie nella pratica clinica: percorsi diagnostici e terapeutici. L Endocrinologo, 2009, 10, 2-15.	0.0	0
293	Complicanze cardiometaboliche e renali nell'iperaldosteronismo primario. L Endocrinologo, 2011, 12, 111-116.	0.0	0
294	Primary aldosteronism: considerations about the evaluation of the aldosterone to renin ratio during canrenone treatment. Journal of Endocrinological Investigation, 2021, 44, 2009-2010.	1.8	0
295	EFFECT OF METERGOLINE ON THE ALDOSTERONE-STIMULATING PROPERTIES OF METOCLOPRAMIDE. , 1983, , 531-536.		0